-

Thermo Fisher Scientific’s Clinical Research Business Named Clinical Research Company of the Year for Third Consecutive Year

WILMINGTON, N.C.--(BUSINESS WIRE)--The PPD clinical research business of Thermo Fisher Scientific has been named Clinical Research Company of the Year at the 2022 PharmaTimes Clinical Researcher of the Year International competition held recently in London.

In addition to the business winning the highest honor again this year, 50 clinical researchers from the company were named finalists within all nine eligible team and individual competition categories.

“For the third year in a row, our colleagues have made their presence known by winning multiple recognitions, including the top title, in this highly regarded competition,” said Amber Lee, senior vice president, clinical operations, clinical research, Thermo Fisher Scientific. “The unwavering dedication, expertise and passion our colleagues put on display at the competition are the same qualities they apply every day to our customers’ vital research initiatives. We believe in sustaining a great culture and providing our colleagues with challenging opportunities for professional growth. This, in turn, supports our ability to recruit, develop and retain top talent to serve our customers.”

The business’ award-winning training and development programs, such as CRA Academy, are a key component in strengthening employees’ skills. The academy guides clinical research associates as they gain real-time work experience with effective training and formal academy-based learning. To date, more than 1,000 professionals have graduated from the program.

The Clinical Researcher of the Year Awards competition, hosted by PharmaTimes, consists of a rigorous series of assessments, including a three-stage competition, where participants give presentations before a panel of experienced industry judges. The event was created to provide clinical research professionals an opportunity to benchmark their skills against their peers in a program of competency-based exercises developed through cross-industry collaboration.

Colleagues from Thermo Fisher’s clinical research business won gold in the Aspiring Clinical Research Associate (CRA) category, silver in the CRA category, silver and bronze in the In-House CRA category, silver in the Team Leader category, bronze in the Clinical Team category, gold and bronze in the Start Up-Singles category, as well as gold and silver in the Start-Up Team category.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.

Contacts

Media Contact Information:
Nadine Maeser
Clinical Research, Thermo Fisher Scientific
(910) 558-4779
nadine.maeser@ppd.com

Thermo Fisher

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)

Release Summary
Thermo Fisher Scientific’s PPD clinical research business has been named Clinical Research Company of the Year for the third consecutive year.
Release Versions

Contacts

Media Contact Information:
Nadine Maeser
Clinical Research, Thermo Fisher Scientific
(910) 558-4779
nadine.maeser@ppd.com

More News From Thermo Fisher

Thermo Fisher Scientific Expands Real-World Data Interoperability and Linkage Through Strategic Collaboration with Datavant

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced a strategic data collaboration with Datavant, the data collaboration platform trusted for healthcare, to make it easier for pharmaceutical and biotech companies to connect real-world data with clinical research—helping them generate stronger evidence, faster. Thermo Fisher’s PPD™ clinical research business and Datavant will enable secure connection and analysis of real-world data (RWD...

Thermo Fisher Scientific Prices Offering of USD-Denominated Senior Notes

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”) announced today that it has priced an offering of $3.8 billion aggregate principal amount (the “Offering”) of the following notes: $1.0 billion aggregate principal amount of its 4.215% senior notes due 2031 (the “2031 notes”) at the issue price of 100.000% of their principal amount; $750 million aggregate principal amount of its 4.550% senior notes due 2033 (the “2033 notes”) at the issue price of 99.78...

Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2025 Results

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter and Full Year 2025 Highlights Fourth quarter revenue grew 7% to $12.21 billion. Fourth quarter GAAP diluted earnings per share (EPS) grew 9% to $5.21. Fourth quarter adjusted EPS grew 8% to $6.57. Full year revenue grew 4% to $44.56 billion. Full year GAAP diluted earning...
Back to Newsroom